The insulin inhaler developer has received $20.5m in a round featuring Koch Industries subsidiary Molex Ventures.
US-based insulin inhaler developer Dance Biopharm has secured approximately $20.5m in a funding round backed by Molex Ventures, a medical electronics subsidiary of manufacturing, chemicals and energy conglomerate Koch Industries.
Molex was joined by a syndicate of institutional and individual investors, and the round follows $24.5m from investors including Molex in September 2018.
Dance Biopharm is developing a handheld device called Dance 501, which is designed to be a needle-free alternative to delivering insulin into a diabetic patient’s lungs, instead…
